Onconova Therapeutics, Inc. filed a letter providing an update on their clinical development program for rigosertib, including positive data from a Phase 1/2 trial in higher-risk myelodysplastic syndromes (HR-MDS) patients.
AI Assistant
TRAWS PHARMA INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.